Mechanism of action
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of endogenous GLP-1, an incretin hormone released from intestinal L-cells in response to food intake.
Primary mechanisms include:
- Glucose-dependent insulin secretion: Stimulates pancreatic beta cells to release insulin only when blood glucose is elevated, minimizing hypoglycemia risk
- Glucagon suppression: Inhibits alpha cell secretion of glucagon in a glucose-dependent manner, reducing hepatic glucose production
- Delayed gastric emptying: Slows the rate at which food leaves the stomach, contributing to satiety and postprandial glucose control
- Central appetite regulation: Acts on hypothalamic receptors to reduce appetite and food intake, leading to weight loss
- Cardiovascular effects: May have cardioprotective properties through multiple pathways including effects on blood pressure, lipid metabolism, and direct cardiac tissue effects
Semaglutide has 94% sequence homology to native human GLP-1 but contains modifications that confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation and promote albumin binding, extending its half-life to approximately one week and allowing once-weekly subcutaneous administration.
- Semaglutide is a GLP-1 receptor agonist with glucose-dependent insulin secretion, minimizing hypoglycemia risk as monotherapy.
- Black box warning: risk of thyroid C-cell tumors; contraindicated in MTC or MEN 2 personal/family history.
- Most common adverse effect is nausea (15-44%), usually transient and dose-dependent.
- Long half-life (~7 days) allows once-weekly subcutaneous dosing; steady state reached in 4-5 weeks.
- Delays gastric emptying, which may affect oral medication absorption and contributes to weight loss.
- SUSTAIN-6 trial showed cardiovascular benefit: reduced MACE in T2DM patients with established CVD.
- Pancreatitis is a serious adverse effect; discontinue if suspected and do not restart if confirmed.
- Increases hypoglycemia risk when combined with insulin or sulfonylureas; consider dose reduction of these agents.
Indications
Approved indications:
- Type 2 diabetes mellitus: As an adjunct to diet and exercise to improve glycemic control in adults; may be used as monotherapy or in combination with other antidiabetic agents including metformin, sulfonylureas, SGLT2 inhibitors, and insulin
- Chronic weight management: In adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as adjunct to reduced-calorie diet and increased physical activity
- Cardiovascular risk reduction: To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease
Off-label uses being investigated include polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), and prevention of type 2 diabetes in high-risk individuals.
Semaglutide is available in multiple formulations: subcutaneous injection for diabetes and weight management, and oral tablet for diabetes only.
Pharmacokinetics
Absorption: After subcutaneous injection, maximum plasma concentration is reached in 1-3 days. Oral semaglutide uses absorption enhancer (SNAC) to facilitate gastric absorption. Bioavailability of subcutaneous formulation is approximately 89%.
Distribution: Highly bound to plasma albumin (>99%). Volume of distribution is approximately 12.5 liters.
Metabolism: Proteolytically cleaved by ubiquitous proteases and peptidases into smaller peptides and amino acids; not metabolized by cytochrome P450 enzymes.
Elimination: Eliminated primarily as metabolized peptide fragments via renal and fecal routes. Half-life is approximately 7 days for subcutaneous formulation, enabling once-weekly dosing. Steady state is reached after 4-5 weeks.
Special populations: No dose adjustment is required for renal impairment, including end-stage renal disease. Use with caution in severe hepatic impairment due to limited data. Age and body weight do not require dose adjustments.
Adverse effects
Gastrointestinal effects (most common):
- Nausea (15-44%, most common, usually transient)
- Vomiting (9-24%)
- Diarrhea (8-30%)
- Constipation (11-24%)
- Abdominal pain (6-20%)
- Dyspepsia
Gastrointestinal adverse effects are dose-dependent and typically improve over time with continued use. Slow dose titration reduces their incidence.
Serious adverse effects:
- Pancreatitis: Acute pancreatitis reported; discontinue if suspected and do not restart if confirmed
- Gallbladder disease: Cholelithiasis and cholecystitis; risk increased with rapid weight loss
- Hypoglycemia: Low risk as monotherapy but increased when combined with insulin or sulfonylureas; dose reduction of these agents may be necessary
- Acute kidney injury: Reported secondary to dehydration from gastrointestinal losses
- Diabetic retinopathy complications: Rapid improvement in glycemic control may temporarily worsen diabetic retinopathy
- Thyroid C-cell tumors: Black box warning based on rodent studies showing dose-dependent thyroid C-cell tumors; contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Other adverse effects:
- Injection site reactions (subcutaneous formulation)
- Increased heart rate (mean increase 1-4 bpm)
- Fatigue
- Dizziness
- Altered taste (oral formulation)
Immunogenicity: Anti-semaglutide antibodies may develop but generally have no clinical impact on efficacy or safety.
Contraindications and warnings
Absolute contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to semaglutide or any formulation component
Warnings and precautions:
- Thyroid C-cell tumors: Black box warning; counsel patients about symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness)
- Pancreatitis: Monitor for signs and symptoms (persistent severe abdominal pain); discontinue if suspected
- Diabetic retinopathy: Use with caution in patients with history of diabetic retinopathy; rapid glycemic improvement may worsen retinopathy
- Hypoglycemia: Risk increased when used with insulin or insulin secretagogues; consider dose reduction of these agents
- Acute kidney injury: Monitor renal function in patients with renal impairment or those experiencing severe gastrointestinal adverse effects
- Hypersensitivity reactions: Serious reactions including anaphylaxis and angioedema reported
- Gallbladder disease: Substantial or rapid weight loss increases risk; monitor for signs and symptoms
- Heart rate increase: Use with caution in patients with cardiovascular disease
Pregnancy and lactation: Limited human data. In animal studies, semaglutide caused structural abnormalities and altered growth at clinically relevant exposures. Discontinue at least 2 months before planned pregnancy due to long washout period. Use during pregnancy only if benefits outweigh risks. Unknown if excreted in breast milk; consider benefits of breastfeeding and maternal need for therapy.
Drug interactions
Pharmacokinetic interactions:
- Oral medications: Semaglutide delays gastric emptying, which may affect absorption of concomitant oral medications. Administer oral medications at least 30-60 minutes before semaglutide injection or consider timing adjustments. Particularly relevant for medications requiring rapid absorption or those with narrow therapeutic index.
- Oral contraceptives: May have reduced efficacy due to delayed gastric emptying; use additional contraceptive methods for 4 weeks after initiation and after dose escalations of oral semaglutide.
Pharmacodynamic interactions:
- Insulin and insulin secretagogues (sulfonylureas, meglitinides): Increased risk of hypoglycemia; consider reducing insulin or secretagogue dose when initiating semaglutide
- Other antidiabetic agents: Generally compatible with metformin, SGLT2 inhibitors, DPP-4 inhibitors, and thiazolidinediones without dose adjustment, though using GLP-1 agonists with DPP-4 inhibitors is not recommended due to overlapping mechanisms
Specific drug considerations:
- Warfarin: Monitor INR more frequently when initiating or changing semaglutide dose due to altered vitamin K absorption from delayed gastric emptying
- Levothyroxine: May require monitoring and dose adjustment due to altered absorption
- Medications requiring rapid absorption: Acetaminophen pharmacokinetics were not significantly affected, but clinical judgment should guide timing for other medications
No clinically significant CYP450-mediated interactions as semaglutide is not metabolized by these enzymes.
Clinical pearls
Exam-relevant points:
- Semaglutide produces more weight loss than most other GLP-1 agonists; average weight reduction of 10-15% of body weight at higher doses used for obesity management
- The once-weekly subcutaneous formulation improves adherence compared to daily GLP-1 agonists
- Nausea is the most common adverse effect and typically decreases over time; slow titration and dietary modifications (smaller, more frequent meals) help minimize symptoms
- Unlike insulin and sulfonylureas, semaglutide has low intrinsic hypoglycemia risk due to glucose-dependent mechanism
- CVOT data: The SUSTAIN-6 trial demonstrated cardiovascular benefits with reduction in major adverse cardiovascular events in patients with type 2 diabetes and cardiovascular disease
- Semaglutide is not first-line for type 1 diabetes and is not a substitute for insulin in type 1 diabetes or diabetic ketoacidosis
Clinical use tips:
- Start with low dose and titrate slowly (every 4 weeks) to minimize gastrointestinal adverse effects
- Inject subcutaneously in abdomen, thigh, or upper arm; rotate injection sites
- Oral semaglutide must be taken on empty stomach with no more than 4 oz water, and patient must wait 30 minutes before eating, drinking, or taking other oral medications
- If a weekly dose is missed, administer as soon as possible within 5 days; if >5 days, skip and resume regular schedule
- Consider as preferred agent in overweight/obese patients with type 2 diabetes given dual benefit on glycemic control and weight reduction
- Monitor for signs of pancreatitis, especially in first months of therapy
- Patient education about thyroid tumor warning signs is essential
Comparison pearls:
- vs. liraglutide: Semaglutide has longer half-life (weekly vs. daily), greater weight loss, and similar gastrointestinal side effect profile
- vs. dulaglutide: Both weekly agents; semaglutide generally associated with greater weight loss and HbA1c reduction
- vs. SGLT2 inhibitors: Both cardioprotective; GLP-1 agonists have lower risk of genital infections and no osmotic diuresis but higher gastrointestinal adverse effects
- vs. metformin: Semaglutide more expensive, more effective for weight loss, similar HbA1c reduction; metformin remains first-line in most guidelines
SEMA-glutide: Suppresses glucagon, Enhances insulin, Minimizes hypoglycemia (alone), Appetite reduction, causes GI upset (nausea), Long half-life, Used for weight loss, Thyroid C-cell tumor warning, Injection weekly, Delays gastric emptying, Excellent for CV risk reduction.
Practice questions
1. A 58-year-old woman with type 2 diabetes mellitus and BMI of 34 kg/m² presents for medication review. Her HbA1c is 8.2% despite metformin 2000 mg daily. She has hypertension and a history of cardiovascular disease. Her sister was recently diagnosed with medullary thyroid carcinoma. Which of the following is the most appropriate next step in management?
2. A 52-year-old man with type 2 diabetes starts semaglutide 0.25 mg weekly along with his existing regimen of metformin and insulin glargine 40 units at bedtime. After 2 weeks, he reports three episodes of symptomatic hypoglycemia with glucose readings between 52-65 mg/dL, occurring in the late afternoon. His fasting glucose remains 110-130 mg/dL. Which of the following is the most appropriate management?
3. A 45-year-old woman with obesity (BMI 38 kg/m²) and prediabetes has been taking semaglutide 2.4 mg weekly for weight management for 6 weeks. She has lost 12 pounds but reports persistent nausea, three episodes of vomiting in the past week, and severe upper abdominal pain radiating to her back for the past 24 hours. Vital signs show temperature 38.1°C (100.6°F), heart rate 104/min, blood pressure 128/82 mmHg. Laboratory studies show lipase 680 U/L (normal <160 U/L). Which of the following is the most appropriate next step?
Frequently asked questions
How does semaglutide work?
Semaglutide is a GLP-1 receptor agonist that works by enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon release, delaying gastric emptying, and reducing appetite through central mechanisms. Its glucose-dependent action means it stimulates insulin only when blood glucose is elevated, which minimizes the risk of hypoglycemia when used alone. The delayed gastric emptying and appetite suppression contribute to significant weight loss, making it effective for both diabetes management and obesity treatment.
What are the side effects of semaglutide?
The most common side effects are gastrointestinal: nausea (15-44%), vomiting, diarrhea, constipation, and abdominal pain, which are usually temporary and improve with continued use. Serious adverse effects include pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury from dehydration, and diabetic retinopathy complications with rapid glycemic improvement. Semaglutide carries a black box warning for thyroid C-cell tumors based on animal studies and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
Is semaglutide a controlled substance?
No, semaglutide is not a controlled substance. It is a prescription medication classified as a GLP-1 receptor agonist and does not have abuse potential or dependence risk. It is regulated as a standard prescription drug requiring healthcare provider authorization but is not subject to DEA scheduling or controlled substance regulations.
Can semaglutide cause hypoglycemia?
Semaglutide has low intrinsic risk of hypoglycemia when used alone because its mechanism is glucose-dependent, meaning it stimulates insulin secretion only when blood glucose is elevated. However, hypoglycemia risk increases significantly when semaglutide is combined with insulin or insulin secretagogues like sulfonylureas. In these combinations, dose reduction of the insulin or sulfonylurea is often necessary to prevent hypoglycemia. Patients should be educated about hypoglycemia symptoms and appropriate management.
Semaglutide vs liraglutide — what is the difference?
Both are GLP-1 receptor agonists, but semaglutide has a longer half-life allowing once-weekly administration while liraglutide requires once-daily injection. Semaglutide generally produces greater weight loss and HbA1c reduction compared to liraglutide at approved doses. Both have similar cardiovascular benefits and black box warnings for thyroid C-cell tumors. The gastrointestinal side effect profiles are comparable, though the longer dosing interval of semaglutide may improve patient adherence and convenience.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A10BJ06
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.